Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis.
比较0.1%溴芬酸钠和0.1%吡嘧司特钾治疗过敏性结膜炎的疗效。
OBJECTIVE a RP-HPLC method for the determination of pemirolast potassium and its related compounds in tablets was developed to control the quality of pemirolast potassium preparations.
目的建立RP HPLC对吡嘧司特钾有关物质检查及其片剂含量的测定方法，为原料与制剂的质量控制提供有效的分析方法。
Clinical studies suggest that pemirolast potassium can prevent and cure variation asthma, anaphylactic rhinitis, anaphylactic conjunctivitis and atopic dermatitis with little untoward reactions.
临床研究显示吡嘧司特钾是变异性哮喘、过敏性鼻炎、过敏性结膜炎和特异性皮炎的防治药物，不良反应较轻。
Clinical studies suggest that pemirolast potassium can prevent and cure variation asthma, anaphylactic rhinitis, anaphylactic conjunctivitis and atopic dermatitis with little untoward reactions.
临床研究显示吡嘧司特钾是变异性哮喘、过敏性鼻炎、过敏性结膜炎和特异性皮炎的防治药物，不良反应较轻。
应用推荐